Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a booth and exhibit a poster at this year’s American Association for Cancer Research (AACR) meeting in Florida, USA (2nd to 6th of April, 2011). The AACR show and exhibition is an important international event discussing the latest developments in cancer research. OGT’s booth will be manned by Gareth Thomson (Director of Genomic Services), John Anson (VP Biomarker Discovery) and Will Colón (Business Development Director, Biomarker Discovery), who will be on hand to discuss OGT’s diagnostic biomarker discovery programmes, as well as its Genefficiency™ genomic service offerings, which include array-based copy number variation, methylation, miRNA and gene expression analysis. As part of this, OGT will also present a poster, entitled “Application of a novel protein biomarker discovery platform to identify biomarkers for improved diagnosis of prostate cancer”, which will provide details of the company’s focus on developing a biomarker panel for prostate cancer.

OGT offers a range of high-quality DNA, RNA and protein based tools and services to help maximise the potential of your research and biomarker discovery projects. To find out more and meet the OGT team, visit our AACR 2011 booth, number 1625. Alternatively, more information can be found online at www.ogt.co.uk.

About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

Alto Marketing

Office 3 Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL

OGT enquiries
Oxford Gene Technology - OGT
Stephen Archibald – Marketing Communications Manager
t: +44 (0)1865 856828
e: stephen.archibald@ogt.co.uk

Media enquiries
Alto Marketing Limited
Paul Avery – Science Writer
t: +44 (0)1489 557672
e: paulavery@alto-marketing.com

This release was published on openPR.